Bethea ED, Chen Q, Hur C, et al. Cost-effectiveness of Treating Acute versus Chronic Hepatitis C Infection Using Direct-Acting Antivirals. AASLD 2017, abstract 24.
Nivolumab plus ipilimumab versus lenvatinib of sorafenib bij inoperabel hepatocellulair carcinoom
jul 2025 | Hepatologie, Immuuntherapie, Maag-darm-leveroncologie